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OBJECTIVES We sought to evaluate the effects of various doses of guanethidine, a sympathoinhibitory drug,
on ventricular function and survival in chronic heart failure (CHF) after myocardial infarction
(MI) in rats.
BACKGROUND Direct inhibition of sympathetic outflow by a sympathoinhibitory drug might be an effective
approach to therapy of CHF. However, recent clinical trials suggest that excessive suppression
of sympathetic activity has an adverse effect on outcome. It remains unclear whether the
beneficial effects of the sympathoinhibitory drug would be modified by its dosage.
METHODS Three doses of guanethidine (low-dose [LG], 1 mg/kg/day; medium-dose, 3 mg/kg/day;
high-dose, 10 mg/kg/day) were administered via an osmotic mini-pump for 4 weeks.
Hemodynamics, left ventricular (LV) diameters, plasma and myocardial norepinephrine (NE)
levels, and survival were determined for four weeks after MI.
RESULTS As compared with MI rats receiving vehicle, LG suppressed LV dilation (9.2  0.9 mm vs.
11.0  0.8 mm, p  0.05) and improved LV fractional shortening (25.0  4.5% vs. 16.4 
4.7%, p  0.05) in association with a reduction of plasma NE levels (520  250 pg/ml vs.
1,000  570 pg/ml, p  0.05), but not with a significant reduction of noninfarcted
myocardial NE levels (154  71 ng/g vs. 207  71 ng/g). Low-dose guanethidine reduced
24-h (6%) and 28-day mortality (6%), as compared with untreated MI rats (36% and 52%,
respectively). High-dose guanethidine also reduced 24-h mortality (12%) but increased
28-day mortality (91%), in association with a depletion of myocardial NE. Medium-dose
guanethidine had no beneficial effects on LV hemodynamics or long-term survival.
CONCLUSIONS These results indicate that the dosage of the sympathoinhibitory drug might be quite
important for the treatment of CHF. (J Am Coll Cardiol 2003;42:541–8) © 2003 by the
American College of Cardiology Foundation
Activation of the sympathetic nerve system is one of the
major pathophysiologic abnormalities leading to the pro-
gression of chronic heart failure (CHF). Activation of
sympathetic outflow is initially a hemodynamic adaptation
to compensate for decreased cardiac function. However, it
leads to an increase in sodium and fluid retention and also
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in peripheral vascular resistance through the renin-
angiotensin-aldosterone system or direct renal and vascular
effects (1). Other adverse effects of increased sympathetic
activity might be directed toward the heart, resulting in the
desensitization or downregulation of beta-adrenergic recep-
tors (2,3), myocyte injury (4,5), and a predisposition to
ventricular arrhythmias (6). The activation of sympathetic
outflow relates to a poor prognosis in patients with CHF
(7). Therefore, direct inhibition of sympathetic activity
might be an effective therapy for CHF. Actually, the
beneficial effects of sympathoinhibitory drugs in the treat-
ment of CHF have been reported (8,9). Moxonidine is a
novel agonist of the central imidazoline receptor and re-
duces sympathetic outflow and circulating levels of norepi-
nephrine (NE) (10). Based on the beneficial effects of
moxonidine on hemodynamics in patients with CHF
(11,12), clinical trials were designed to evaluate the effects of
moxonidine on plasma NE concentration (Moxonidine
Safety and Efficacy [MOXSE] study) (13) and on mortality
and morbidity (Moxonidine Congestive Heart Failure
[MOXCON] trial) (14) in patients with CHF. Although
plasma NE concentrations were significantly reduced, there
was a significant increase in adverse effects in the MOXSE
study, and the MOXCON study was stopped early because
of increasing mortality in the moxonidine group. These
findings suggest that sympathoinhibition worsens clinical
outcomes in CHF. However, pharmacologic therapy with
angiotensin-converting enzyme inhibitors (15) or beta-
adrenergic blockers (16) provided evidence that the inhibi-
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tion of sympathetic activation improves morbidity and
mortality in patients with CHF. It is not fully elucidated
whether the sympathoinhibitory drugs are useful in the
treatment of CHF.
One possibility for the negative results of the MOXCON
study could be the higher dosage of moxonidine, leading to
an excessive reduction in plasma NE, because a dose-related
increase in serious adverse events was observed in the
MOXSE study. This suggests that excessive suppression of
sympathetic activity could be harmful, as increased sympa-
thetic activity would compensate for decreased cardiac
function. The MOXCON study raises the question of
whether there is an optimal dosage of sympathoinhibitory
drug for the treatment of CHF. We hypothesized that the
beneficial effects of the sympathoinhibitory drug might be
modified by its dosage. The present study was therefore
designed to elucidate the effects of various doses of guaneth-
idine on ventricular function and survival in heart failure
after myocardial infarction (MI) in rats.
METHODS
The present study was undertaken in accordance with the
guidelines for animal experiment at Toyama Medical and
Pharmaceutical University.
Experimental animals. Male Wistar rats weighing 300 to
350 g were used for induction of MI. Myocardial infarction
was produced by ligation of the left coronary artery under
ether anesthesia, as reported previously (17). Briefly, the
chest was opened by a left lateral thoracotomy, and the left
coronary artery was ligated approximately 2 to 3 mm from
its origin with a suture of 6-0 silk. Control rats received a
sham operation by using a similar procedure without coro-
nary ligation.
Two days before the surgical procedure, the rats were
randomized to the guanethidine group, which received
subcutaneous implantation of osmotic mini-pumps (Alzet,
ALZA Pharmaceuticals, Palo Alto, California) filled with
guanethidine, or the control group, which received vehicle.
In our preliminary study, four different doses of guanethi-
dine (0.3, 1.0, 3.0, or 10.0 mg/kg/day) were given for two
weeks, using the mini-pumps in normal rats to determine
the effects on plasma NE concentrations and left ventricular
(LV) NE contents. As shown in Table 1, guanethidine
induced a dose-dependent decrease in plasma and myocar-
dial NE levels. Accordingly, a low dose of guanethidine
(LG) (1 mg/kg/day) was chosen as the dose not to reduce
myocardial NE; a medium dose (MG) (3 mg/kg/day) to
deplete myocardial NE moderately; and a high dose (HG)
(10 mg/kg/day) to deplete myocardial NE severely.
Guanethidine was dissolved in saline and adjusted to pro-
vide a daily dose of 1 mg/kg (LG), 3 mg/kg (MG), or 10
mg/kg (HG). Before the induction of MI, rats were
classified into four groups: LG (n 17), MG (n 20), HG
(n  34), and saline vehicle (n  25). The sham-operated
rats were also classified into two groups: HG (n  7) and
vehicle (n  6). The mini-pump was replaced every two
weeks under ether anesthesia. The administration of
guanethidine was continued throughout the study period
(i.e., 4 weeks).
Infarct size was determined using a technique described
by Chien et al. (18). Briefly, after sacrifice of the rats with an
overdose of pentobarbital (70 mg/kg intraperitoneally), the
right ventricle (RV) and LV, including the interventricular
septum, were dissected, separated, and weighed. Incisions
were made in the LV so that the LV tissue could be pressed
flat. The LV circumference and region of infarction were
outlined on a clear plastic sheet for both the endocardial and
epicardial surfaces. The difference in weight between the
two marked areas on the sheet was used to determine the
relative size of MI, which was expressed as a percentage of
LV surface area.
Hemodynamic study and measurement of catecholamines.
Four weeks after MI induction or sham operation, trans-
thoracic echocardiography was performed under ether an-
esthesia with a 7.5-MHz transducer (SSH140A, Toshiba,
Japan), as described previously (17). Left ventricular end-
diastolic and end-systolic internal dimensions (LVEDD
and LVESD, respectively) and fractional shortening were
determined from at least three consecutive cardiac cycles.
After echocardiographic data collection, a 2F micro-
manometer-tipped catheter was inserted into the right
carotid artery and advanced into the LV to determine LV
pressure under light anesthesia. The signals of LV pressure
were digitized on-line at a sampling interval of 2 ms and
Abbreviations and Acronyms
BW  body weight
CHF  chronic heart failure
HG  high-dose guanethidine
LG  low-dose guanethidine
LV  left ventricle/ventricular
LVEDD  left ventricular end-diastolic dimension
LVESD  left ventricular end-systolic dimension
MG  medium-dose guanethidine
MI  myocardial infarction
MOXCON  Moxonidine Congestive Heart Failure
trial
MOXSE  Moxonidine Safety and Efficacy study
NE  norepinephrine
RV  right ventricle/ventricular
Table 1. Effects of Guanethidine on Plasma NE Concentration
and LV NE Contents in Normal Rats
Guanethidine Dose, mg/kg/day
0.3
(n  4)
1.0
(n  5)
3.0
(n  5)
10.0
(n  4)
Plasma NE
(pg/ml)
600  100 540  160 320  70 230  50*†
LV NE (ng/g) 587  81 547  138 81  8*† 22  6*†
*p  0.05 vs. 0.3 mg/kg/day. †p  0.05 vs. 1.0 mg/kg/day. Data are presented as the
mean value  SD.
LV  left ventricular; NE  norepinephrine.
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analyzed with a signal processing computer system (7T-18,
NEC, San-Ei, Japan).
After blood sampling for analysis of plasma cat-
echolamines, the chest was opened to remove the heart
quickly. The RV and LV were dissected, rinsed in ice-cold
saline, and weighed, and the infarct size was then deter-
mined as mentioned earlier. Plasma and noninfarcted LV
tissue samples were stored at 80°C for later analyses.
Tissue and plasma catecholamines were determined by
automated high-performance liquid chromatography, as
described previously (19).
Statistical analysis. Results are expressed as the mean
value  SD. The group differences in body weight, ventric-
ular weight, infarct size, hemodynamic and echocardio-
graphic data, and plasma and myocardial NE levels were
tested with one-way analysis of variance without repetition,
followed by the Bonferroni test for multiple comparisons.
Survival was analyzed by using standard Kaplan-Meier
analysis with the log-rank test. The mortality at 24 h and 28
days after MI, with or without guanethidine treatment, was
tested by the chi-square test. All analytical results were
obtained using StatView for Windows, version 4.5 (Abacus
Concepts Inc., Berkeley, California). A p value 0.05 was
considered statistically significant.
RESULTS
Hemodynamics and LV geometry. In sham-operated rats,
HG reduced body weight (BW) but did not affect LV mass
and RV mass indexed for BW (LV/BW and RV/BW,
respectively), as shown in Table 2. In MI rats, the infarct
size did not differ between untreated and guanethidine-
treated rats. The MI rats had a greater RV/BW ratio than
sham-operated rats. Low-dose guanethidine did not change
the LV/BW or RV/BW ratio. Rats treated with MG had a
greater LV/BW ratio.
As compared with sham-operated rats, MI rats had
elevated LV end-diastolic pressure and decreased maximum
and minimum values of the rate of change in LV pressure
(dP/dt) (Table 2). Low-dose guanethidine tended to lower
LV end-diastolic pressure. However, the hemodynamic
indexes of heart rate, mean arterial pressure, or dP/dt were
not different among MI rats with or without guanethidine
treatment (LG and MG). Hemodynamic and echocardio-
graphic data in MI rats treated with HG were obtained
from only three animals, because other rats died during the
study period. As shown in Table 2, the surviving rats had a
similar infarct size and increased ratio of ventricular weight
to body weight, as compared with untreated MI rats. The
heart rate or arterial pressure was not decreased with HG.
The LV hemodynamics could be obtained from only one
animal whose end-diastolic pressure was markedly elevated.
An autopsy was performed in nine MI rats with HG that
died during the study period. The average infarct size of
these rats was 34.7  3.4%, which was not different from
that of untreated or LG- or MG-treated MI rats. Most of
these rats had pleural effusion and increased lung weight,
suggesting pulmonary congestion. In sham-operated rats,
HG did not affect the aforementioned hemodynamic in-
dexes.
Figure 1 shows echocardiographic data. In sham-
operated rats, HG did not affect LVEDD (7.1  0.5 mm
vs. 6.7  0.2 mm), LVESD (3.5  0.3 mm vs. 3.3  0.5
mm), or fractional shortening (50.2  3.0% vs. 50.5 
6.5%). In untreated MI rats, LVEDD and LVESD were
increased and fractional shortening was decreased, as com-
pared with sham-operated rats. In contrast, LG significantly
reduced LVEDD (9.2  0.9 mm vs. 11.0  0.8 mm, p 
0.05) and LVESD (6.9  0.9 mm vs. 9.2  0.8 mm, p 
0.05) and improved fractional shortening (25.0  4.5% vs.
16.4  4.7%, p  0.05). Medium-dose guanethidine
reduced LVEDD (9.8  0.6 mm, p  0.05 vs. untreated
MI rats) but did not improve fractional shortening (14.6 
3.8%). The echocardiographic indexes were not improved
with HG (LVEDD  11.0  0.6 mm, LVESD  9.5 
0.7 mm, fractional shortening  13.4  5.0%).
Plasma and myocardial NE. Plasma and myocardial NE
levels are shown in Figure 2. In sham-operated rats, HG
markedly decreased myocardial NE (21  7 ng/g vs. 494 
Table 2. Body Weight, Ventricular Weight, and Hemodynamic Data 28 Days After Myocardial Infarction
Sham
(n  6)
ShamHG
(n  7)
MI
(n  12)
MILG
(n  13)
MIMG
(n  8)
MIHG
(n  3)
Body weight (g) 410  32 339  7* 366  32 371  23 341  19* 297  45
LV/BW (mg/g) 1.83  0.13 2.06  0.12 1.96  0.20 2.10  0.16 2.16  0.27* 2.59  0.17
RV/BW (mg/g) 0.43  0.05 0.50  0.08 0.88  0.24* 0.78  0.23* 0.93  0.23* 1.15  0.15
Infarct size (%) — — 33.9  6.7 32.4  8.6 31.9  4.0 32.6  0.9
HR (beats/min) 406  22 412  20 395  21 373  31 384  14 389  10
Mean arterial pressure (mm Hg) 90  11 90  8 83  13 76  9 87  11 92  3
LVSP (mm Hg) 108  6 113  8 104  12 101  8 112  10 117
LVEDP (mm Hg) 2  2 3  2 18  7* 14  7* 18  12* 24
Peak dP/dt (103 mm Hg/s) 10.4  1.6 10.9  1.0 7.3  1.6* 7.1  1.4* 7.5  1.8* 7.2
Peak dP/dt (103 mm Hg/s) 6.9  1.7 7.1  0.8 4.5  1.1* 4.3  0.1* 4.4  0.7* 4.3
*p  0.05 vs. sham-operated rats. Left ventricular hemodynamic data in MIHG were obtained from one rat. The difference between MIHG rats and the other groups was
not compared because of the small number. Data are expressed as the mean value  SD.
BW  body weight; HG  high-dose guanethidine; HR  heart rate; LG  low-dose guanethidine; LV  left ventricle; LVEDP  left ventricular end-diastolic pressure;
LVSP  left ventricular systolic pressure; MG  medium-dose guanethidine; MI  rats with myocardial infarction; Peak dP/dt and dP/dt  peak positive and negative
value of rate of change in left ventricular pressure; RV  right ventricle; Sham  sham-operated rats.
543JACC Vol. 42, No. 3, 2003 Igawa et al.
August 6, 2003:541–8 Effects of Guanethidine in Heart Failure
100 ng/g, p  0.05). In untreated MI rats, plasma NE was
elevated and the NE content of noninfarcted LV was
decreased, as compared with sham-operated rats. Low-dose
guanethidine significantly reduced plasma NE (520  250
pg/ml vs. 1,000  570 pg/ml, p  0.05) but did not
significantly affect myocardial NE (154 71 ng/g vs. 207
71 ng/g, p  NS) in MI rats. Medium-dose guanethidine
reduced plasma (570  230 pg/ml, p  0.05 vs. untreated
MI rats) and myocardial NE (47  18 ng/g, p  0.05 vs.
untreated MI rats). The myocardial NE of surviving MI rats
treated with HG was markedly reduced (9 6 ng/g, n 3).
Mortality. The Kaplan-Meier survival curves of sham-
operated rats and MI rats are shown in Figure 3. In
sham-operated rats, HG did not affect survival. The survival
of MI rats treated with LG improved markedly, as com-
pared with untreated MI rats. The survival of MI rats
treated with MG was not different from that of untreated
MI rats. In contrast, MI rats treated with HG showed the
worst survival, and most of the rats died during the study
period. Figure 4 shows 24-h and 28-day mortality after MI.
The 24-h mortality rate was 36% in untreated MI rats.
Low-, medium-, and high-dose guanethidine reduced 24-h
mortality to 6%, 15%, and 12%, respectively. The 28-day
mortality rate of untreated MI rats was 52%. Low-dose
guanethidine reduced 28-day mortality to 6% (p  0.05 vs.
untreated MI rats), but HG increased mortality to 91% (p
 0.05 vs. untreated MI rats).
DISCUSSION
The major findings of the present study are as follows. First,
LG attenuated LV dilation and improved ventricular func-
tion after MI, in association with a reduction of plasma NE
concentration, but with no significant influence on myocar-
dial NE contents. Secondly, sympathoinhibition by LG,
MG, and HG reduced mortality in the acute stage after MI,
as compared with untreated MI. As for the long-term effect,
however, LG reduced mortality, but HG markedly in-
creased it. These results indicate that the beneficial effects of
the sympathoinhibitory drug might be affected by its dosage
in the treatment of CHF.
Guanethidine acts on the adrenergic nerve terminal and
inhibits release and storage of NE, resulting in a decrease in
peripheral vascular resistance and systemic blood pressure
(20). As shown in our preliminary study, guanethidine
suppressed sympathetic activity in a dose-dependent man-
ner. In sham-operated rats, HG markedly decreased plasma
and myocardial NE levels but did not significantly affect the
Figure 1. Echocardiographic variables of sham-operated rats (SH) (n  6), SH rats treated with high-dose guanethidine (SHHG) (n  7), rats with
myocardial infarction receiving vehicle (MI) (n  12), and MI rats treated with low-dose guanethidine (MILG) (n  13), medium-dose guanethidine
(MIMG) (n  8), and high-dose guanethidine (MIHG) (n  3). *p  0.05 vs. sham-operated rats. †p  0.05 vs. MI rats. ‡p  0.05 vs. MILG
rats. The difference between MIHG rats and the other groups was not compared because of the small number. Data are presented as the mean value 
SD. FS  fractional shortening of left ventricle; LVEDD and LVESD  left ventricular end-diastolic and end-systolic dimension, respectively.
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heart rate, mean arterial pressure, or LV function. This
suggests that a level of sympathetic activity in normal rats at
rest may be too low for guanethidine to change LV
performance.
In the present study, LG attenuated LV dilation and
improved ventricular function after MI. There may be
several possible explanations for the improvement in ven-
tricular function by guanethidine. First, LG tended to lower
Figure 2. Plasma norepinephrine (NE) concentrations (left panel) and NE contents of noninfarcted left ventricle (right panel) of sham-operated rats (SH)
(n  6), SH rats treated with high-dose guanethidine (SHHG) (n  7), rats with myocardial infarction receiving vehicle (MI) ( n  12), and MI rats
treated with low-dose guanethidine (MILG) (n  13), medium-dose guanethidine (MIMG) (n  8), and high-dose guanethidine (MIHG) (n 
3). The plasma NE concentration of MIHG rats was not measured. *p  0.05 vs. sham-operated rats. †p  0.05 vs. MI rats. ‡p  0.05 vs. MILG
rats. The difference between MIHG rats and the other groups was not compared because of the small number. Data are presented as the mean value 
SD.
Figure 3. Kaplan-Meier survival curves of sham-operated rats treated with high-dose guanethidine (SHHG) (n  7), rats with myocardial infarction
receiving vehicle (MI) (n  25), and MI rats treated with low-dose guanethidine (MILG) (n  17), medium-dose guanethidine (MIMG) (n  20),
and high-dose guanethidine (MIHG) (n  34). Survival of sham-operated rats receiving vehicle (100%) is not shown. *p  0.05 vs. MI rats. †p 0.05
vs. MIMG rats.
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mean arterial pressure and LV end-diastolic pressure, sug-
gesting a trend toward a reduction of LV preload and
afterload. The changes in the ventricular loading condition
by guanethidine might improve LV function. Moreover,
decreases in heart rate and LV load condition might have a
favorable effect on cardiac energy metabolism. Secondly,
inhibition of NE release by LG at the cardiac nerve terminal
might decrease the local NE concentration to protect the
LV from the adverse effects of NE in MI rats. In heart
failure, increased NE release and an impaired re-uptake
mechanism at the cardiac nerve terminal result in an
increase in the synaptic NE concentration (21). The in-
creased local NE may lead to alteration of beta-adrenergic
signaling (2,3,22), myocyte injury (4,5), and cellular hyper-
trophy (23). Administration of guanethidine early in the
development of heart failure partially prevented depression
of responsiveness to beta-adrenergic stimulation (24). The
suppression of myocyte injury and hypertrophy by the
sympathoinhibitory drug moxonidine might reduce intersti-
tial fibrosis (25). These alterations were beneficial in the
treatment of CHF. Thirdly, we have previously reported
that renal sympathetic denervation suppressed renal sodium
reabsorption and thereby improved ventricular function in
rats with MI (26). Suppression of renal sympathetic activity
by LG may decrease sodium and water retention, leading to
attenuation of LV dysfunction after MI.
In contrast to LG, HG unexpectedly worsened the
survival of rats with MI. The present data indicate that HG
did not attenuate LV dilation and LV dysfunction, despite
a marked reduction of myocardial NE. The Valsartan Heart
Failure Trial (Val-HeFT) raises a hypothesis that extensive
blockade of multiple neurohormonal systems could be
deleterious in the treatment of heart failure, because valsar-
tan had an adverse effect on mortality and morbidity in
patients receiving both angiotensin-converting enzyme in-
hibitors and beta-blockers (27). The recent study of nepi-
castat, a dopamine beta-hydroxylase inhibitor that inhibits
synthesis and release of NE, clearly showed the effect was
dependent on the dosage (28). That is, low-dose nepicastat
prevented progressive LV dysfunction and remodeling, but
high-dose nepicastat worsened them, despite greater adren-
ergic inhibition, as compared with low-dose treatment.
Low-dose nepicastat normalized transmyocardial plasma
NE, but high-dose nepicastat depleted it below the normal
level. These results are consistent with the present study.
Low-dose guanethidine that normalized plasma NE but did
not deplete myocardial NE was favorable for LV function
and mortality. However, the beneficial effects of guanethi-
dine were lost when MG or HG that depleted myocardial
NE was used. Taken together, these results suggest that
excessive inhibition of adrenergic drive in CHF could have
an adverse effect on cardiac function and remodeling, and
some levels of sympathetic activity might be preserved for
the treatment of CHF.
Increased sympathetic activity could relate to induction of
ventricular arrhythmias, especially in cases of acute myocar-
dial ischemia (29). Increased alpha1- and beta-adrenergic
receptor activation by NE and heterogeneous sympathetic
innervation in the ischemic heart play a role in a predispo-
sition to ventricular arrhythmias (30). Indeed, ventricular
arrhythmias such as ventricular tachycardia were frequently
observed after coronary artery ligation in the present study.
Although we did not determine the frequency of ventricular
arrhythmias in detail, rats treated with guanethidine had
fewer episodes of ventricular tachycardia for approximately
20 min after coronary ligation. Suppression of NE release by
Figure 4. The 24-h and 28-day mortality of rats with myocardial infarction receiving vehicle (MI) (n 25) and MI rats treated with low-dose guanethidine
(MILG) (n  17), medium-dose guanethidine (MIMG) (n 20), and high-dose guanethidine (MIHG) (n 34). *p  0.05 vs. MI rats. †p  0.05
vs. MILG rats. ‡p  0.05 vs. MIMG rats.
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guanethidine may prevent ventricular arrhythmias and
thereby improve mortality in the acute stage after MI.
Guanethidine has several pharmacologic effects unrelated
to direct cardiac sympathetic inhibition. First, guanethidine
is concentrated in adrenergic nerve terminals and exerts a
selective local anesthetic effect at this site (31). This anes-
thetic effect of guanethidine inhibits NE release at the nerve
terminal (31) and might reduce arrhythmic deaths during
the first 24 h after MI in guanethidine groups. Secondly,
guanethidine initially releases NE and might have a sym-
pathomimetic effect on the cardiovascular system when
given intravenously (32). However, this does not occur with
oral administration (33). In the present study, we measured
blood pressure and heart rate in five rats before and two days
after HG administration (before MI induction). After HG
administration, there was no increase in systolic blood
pressure or heart rate (119 11 to 121 7 mm Hg and 376
 21 to 328  13 beats/min, respectively). In the chronic
stage, subcutaneous administration of guanethidine did not
increase the heart rate in sham-operated rats or MI rats.
Therefore, we think the dosage of guanethidine we used in
the present study might not have significant sympathomi-
metic effects. Thirdly, inhibition of neuronal uptake of NE
induced by guanethidine might increase the interstitial NE
level in the heart. However, in the chronic stage after
administration, guanethidine depletes NE storage and re-
duces NE release in the nerve terminal (34). In the present
study, the level of plasma NE was decreased by LG and MG
in MI rats. So, we think that a significant increase in
myocardial interstitial NE induced by guanethidine did not
occur in MI rats, at least in long-term treatment with
guanethidine. This might also be supported by the report
that long-term guanethidine treatment increases cardiac
beta-adrenergic receptors (35).
Some methodologic limitations deserve comment to in-
terpret the present results. First, we could not fully evaluate
the effects of HG on LV function and ventricular remod-
eling in MI rats because of the higher mortality. The
mechanism of the adverse effects of HG remains to be
elucidated. However, the autopsy of MI rats treated with
HG suggests that these rats died of heart failure. Secondly,
the mode of action of guanethidine is different from that of
other sympathoinhibitory drugs such as moxonidine. More-
over, there was no direct evidence that the effects of
guanethidine contribute to sympathoinhibition. A further
study will be required to clarify the importance of the degree
of sympathoinhibition using a central sympathoinhibitory
drug. Thirdly, we did not measure the infarct sizes of some
rats that died during the study period. However, almost the
same site of the coronary artery was ligated for induction of
MI. In our previous study (17), the infarct size was about
36%, using the same methods for induction of MI as in the
present study, and did not vary from the experimental
groups. This value is similar to that in the present study.
Actually, the infarct size of some rats treated with HG that
died during the study period was not different from that of
the other MI rats. Small differences in infarct size among
the four groups of MI might not significantly influence the
present results. Fourthly, there was no direct measurement
of changes in LV contractility with guanethidine treatment,
as the echocardiographic parameters were influenced by the
LV loading condition. Finally, in the present study, we
started guanethidine treatment two days before the coronary
ligation. The sympathetic activation and increase in plasma
catecholamines occurred immediately after the coronary
occlusion (36). The degree of sympathetic activation might
be most potent at the onset of MI because it compensates
for acute hemodynamic deterioration. To suppress the
sympathetic activation occurring immediately after MI,
guanethidine was started before the coronary ligation in this
study.
Although limited for these reasons, the present study
suggests that the dosage of the sympathoinhibitory drug is
quite important in the treatment of CHF.
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